FDA Approvals Expand Initial Treatment Options for Multiple Myeloma - Cancer Currents Blog

Edward Lance Lorilla
By -
0
Having trouble viewing this email? View it as a Web page.
Latest from Cancer Currents
01/07/2025
FDA's approvals of Darzalex Faspro and Sarclisa, each used in combination with standard three-drug treatment regimens, should change the initial treatment of newly diagnosed multiple myeloma, including for patients who can't get a stem cell transplant.

Read the Story

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Bookmark and Share

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo

Post a Comment

0Comments

Post a Comment (0)